Stay updated with breaking news from Data ending. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Local Hive™, the #1 brand in natural food stores, according to SPINS Latest 52 Week Data Ending 12/31/23, has proudly been bringing 100%...
/CNW/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY®...
LAVAL, QC, Jan. 21, 2021 /PRNewswire/ -- Bausch & Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY ® (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops have received approval from the Ministry of Food and Drug Safety (MFDS) in South Korea. "The approval of LUMIFY in South Korea marks another step in our global rollout of these innovative redness reliever eye drops," said Thomas J. Appio, president, Bausch + Lomb/International. "LUMIFY will be a welcome addition to our portfolio of eye health products in South Korea, and we expect LUMIFY will be available to consumers in South Korea in the second half of 2021."